Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | June 27, 2022 | June 30, 2022 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
| SOPHIRIS BIO INC.SPHS · Entity 152909 | Director | June 27, 2019 | June 28, 2019 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | June 24, 2022 | June 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date June 27, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27 | Direct | 115,919 |
Reported balance
After 2022-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 93,750 |
Reported balance
After 2022-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.
F5: Not applicable.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
SOPHIRIS BIO INC.
Report date June 27, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2029-06-26 | Direct | 20,000 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 20,000 · Balance 20,000 F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program.
F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.
Ultragenyx Pharmaceutical Inc.
Report date June 24, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,745 |
Reported balance
After 2022-06-24 transaction · row 1
1 source rowRow 1 · 2022-06-24 · Grant · Acquired 3,300 · Balance 17,745 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.57 · Expires 2032-06-24 | Direct | 6,245 |
Reported balance
After 2022-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-24 · Grant · Acquired 6,245 · Balance 6,245 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 3,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 37,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 16, 2026 01:28 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0000905148-26-002469 · form4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Ordinary Shares · 27,000 shares Expires 2036-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:51 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 20,183 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000905148-25-001831 · form4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,183 Underlying: Ordinary Shares · 20,183 shares Expires 2035-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:38 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0000905148-24-001536 · form4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 17, 2023 Filed May 20, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $76.00 | $0.00 |
DisclosureSEC source: 0001140361-23-025828 · form4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2024 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 15,834 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · derivative · entry 9 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,834 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option would have expired in approximately one month and would have been forfeited to the extent it was not exercised on or prior to January 29, 2023. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 69 | $60.85 | $4,198.42 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 8 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The transaction was executed in multiple trades in prices ranging from $60.77 to $61.00, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 10 | $59.46 | $594.60 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 7 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,523 | $58.67 | $89,353.19 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 6 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $58.195 to $58.92, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,303 | $56.98 | $74,243.51 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 5 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,845 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $56.76 to $57.31, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,621 | $56.33 | $372,970.20 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,148 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $55.76 to $56.755, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,897 | $55.35 | $160,340.84 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,769 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $54.75 to $55.74, inclusive. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,411 | $54.15 | $184,706.67 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,666 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $53.74 to $54.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 7 of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:42 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,834 | $6.41 | $101,495.94 |
DisclosureSEC source: 0001567619-23-000574 · doc1.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 15,834 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-044319 · form4.xml · derivative · entry 4 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,834 Underlying: Ordinary Shares · 15,834 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately two months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,021 | $62.12 | $374,018.50 |
DisclosureSEC source: 0001140361-22-044319 · form4.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $61.66 to $62.62, inclusive. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,813 | $61.28 | $601,387.74 |
DisclosureSEC source: 0001140361-22-044319 · form4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,264 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $60.65 to $61.6475, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 and 3 of this Form 4. Read SEC document |
| December 01, 2022 Filed Dec 3, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,834 | $6.41 | $101,495.94 |
DisclosureSEC source: 0001140361-22-044319 · form4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 15,833 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · derivative · entry 6 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,668 Underlying: Ordinary Shares · 15,833 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately three months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,661 | $64.94 | $107,867.67 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · nonDerivative · entry 5 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $64.86 to $65.16, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,312 | $64.26 | $212,824.48 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $63.83 to $64.815, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,717 | $62.91 | $108,012.86 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,216 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $62.57 to $63.27, inclusive. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,143 | $62.01 | $566,952.86 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,933 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $61.56 to $62.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,833 | $6.41 | $101,489.53 |
DisclosureSEC source: 0001140361-22-039911 · form4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 15,833 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · derivative · entry 6 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,501 Underlying: Ordinary Shares · 15,833 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 29, 2013, and all shares subject to the option were fully vested and exercisable January 29, 2014. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,693 | $62.96 | $106,592.80 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · nonDerivative · entry 5 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $62.66 to $63.47, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,355 | $62.11 | $394,677.28 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · nonDerivative · entry 4 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $61.61 to $62.47, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,277 | $61.07 | $261,207.51 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · nonDerivative · entry 3 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,291 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $60.60 to $61.59, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,508 | $60.32 | $211,603.96 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,568 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $59.60 to $60.59, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 01:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 15,833 | $6.41 | $101,489.53 |
DisclosureSEC source: 0001567619-22-018291 · doc1.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 31,666 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-035561 · form4.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,334 Underlying: Ordinary Shares · 31,666 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the option are fully vested exercisable as of the date hereof. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 31,666 | $48.09 | $1,522,817.94 |
DisclosureSEC source: 0001140361-22-035561 · form4.xml · nonDerivative · entry 2 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 31,666 | $6.41 | $202,979.06 |
DisclosureSEC source: 0001140361-22-035561 · form4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 30, 2022 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005402 · primarydocument.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Ordinary Shares · 93,750 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 27, 2022 Filed Jun 30, 2022 00:04 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 115,919 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001562180-22-005402 · primarydocument.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,919 Underlying: Ordinary Shares · 115,919 shares Expires 2032-06-27 F1 · derivative.exercise_date: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039567 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 17:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039567 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,745 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| May 18, 2022 Filed May 28, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001140361-22-021103 · form4.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $93.20 | $0.00 |
DisclosureSEC source: 0001209191-21-043543 · doc4.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043543 · doc4.xml · nonDerivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,445 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:01 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 38,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004325 · primarydocument.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Ordinary Shares · 38,000 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On June 14, 2021, the Reporting Person was granted 38,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 00:01 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 48,506 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004325 · primarydocument.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,506 Underlying: Ordinary Shares · 48,506 shares Expires 2031-06-14 F1 · derivative.exercise_date: On June 14, 2021, the Reporting Person was granted an option to purchase 48,506 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 19, 2021 Filed May 21, 2021 21:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.97 | $0.00 |
DisclosureSEC source: 0001567619-21-010955 · doc1.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2022 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,315 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 6 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,315 Underlying: Ordinary Shares · 6,315 shares Expires 2027-05-18 F4 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,000 of the issuer's ordinary shares granted to the reporting person on May 18, 2017. In exchange, the reporting person received a replacement option, for 6,315 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $56.23 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 5 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,000 shares Expires 2027-05-18 F4 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,000 of the issuer's ordinary shares granted to the reporting person on May 18, 2017. In exchange, the reporting person received a replacement option, for 6,315 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,426 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 4 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 Underlying: Ordinary Shares · 8,426 shares Expires 2026-05-20 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 20, 2016. In exchange, the reporting person received a replacement option, for 8,426 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $42.50 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 3 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2026-05-20 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 20, 2016. In exchange, the reporting person received a replacement option, for 8,426 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,803 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,803 Underlying: Ordinary Shares · 9,803 shares Expires 2025-05-22 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 22, 2015. In exchange, the reporting person received a replacement option, for 9,803 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:43 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $34.04 | Not disclosed |
DisclosureSEC source: 0001567619-21-004313 · doc1.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2025-05-22 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 22, 2015. In exchange, the reporting person received a replacement option, for 9,803 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 00:02 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 28,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005122 · primarydocument.xml · derivative · entry 2 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,702 Underlying: Ordinary Shares · 28,702 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted 28,702 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 00:02 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 36,739 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001562180-20-005122 · primarydocument.xml · derivative · entry 1 Ekman Lars · CIK 0001376117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,739 Underlying: Ordinary Shares · 36,739 shares Expires 2030-07-13 F1 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted an option to purchase 36,739 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in 2021. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.